Kornimate/medical-research-clean huggingface dataset:
a smartphone app on medication adherence

Conditions: Medication Adherence

Summary: this is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (medadhere app) among schizophrenic patients for eight weeks.

schizophrenia is a mental disorder that causes severe functional disabilities and imposes a heavy economic burden. poor medication adherence is one of the major causes of relapse of psychiatric symptoms in schizophrenic patients. this is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (medadhere app) among schizophrenic patients for eight weeks.

Eligibility criteria:
inclusion criteria: * schizophrenia * aged 20 to 65 years * able to read traditional chinese * owning a smartphone * currently admitted at a psychiatric day-care center exclusion criteria: * intellectually disabled or severe cognitive function impairment (dementia)

Keywords: schizophrenia medication adherence smartphone app psychiatric symptoms
neurostimulation to improve nows outcomes

Conditions: Neonatal Opioid Withdrawal Syndrome; Neonatal Abstinence Syndrome

Summary: the objective of this study is to determine if tan therapy can reduce the median number of days of oral morphine administered to an infant after start of treatment.

this study is designed as a randomized, double-blind, sham-controlled, multi-center, clinical trial in which neonates diagnosed with neonatal opioid withdrawal syndrome (nows) will be randomized 1:1 into one of two treatment groups: 1. group 1: active tan + morphine 2. group 2: sham tan + morphine morphine dosing for all infants will be managed by using the finnegan neonatal abstinence scoring system (fnass), recorded every three hours. after the participant exits the inpatient treatment phase of the study, they will enter the neurodevelopmental follow-up phase. the participant's parent or legal guardian will be contacted at 3, 9, 18, and 24 months of age to complete the ages and stages questionnaire (asq-3) and the sensory profile 2 (sp-2). at 24 months, participants who fail in any sub-domain will be referred to their primary care physician for further neurodevelopmental assessment using the bayley scale of infant and toddler development iii (bsid-iii) or other neurodevelopmental assessment.

Eligibility criteria:
inclusion criteria 1. neonates or infants \>33 weeks gestational age with nows who have withdrawal scores requiring morphine replacement therapy 2. clinically stable without respiratory support (exception for nasal cannula) 3. congenital syndromes may be included if the infants do not have major, unrepaired anomalies exclusion criteria 1. unstable infants 2. repeated episodes of autonomic instability (apnea or bradycardia) which are not self-resolving 3. major unrepaired congenital anomalies impacting respiratory or cardiovascular system 4. cardiomyopathy 5. abnormal ear anatomy preventing the device to fit 6. infants diagnosed with iatrogenic nows 7. infants two weeks of age or older (after birth) 8. neonates who have received more than 6 methadone doses or 24 hours of methadone dosing 9. infants who are wards of the state 10. participant has any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Keywords: auricular neurostimulation vagus nerve stimulation transcutaneous withdrawal symptoms
outcomes of robotic total hip arthroplasty

Conditions: Osteoarthritis

Summary: the objectives of this study are to evaluate the clinical value of robotic-assisted total hip arthroplasty with respect to acetabular cup implantation, and to document the long-term clinical outcome of patients with total hip arthroplasty (tha). irb approval will be obtained at every study site to evaluate the basic clinical outcomes and post-operative component placement accuracy of each mako® tha patient. the hypothesis is that robotic preparation of the acetabulum will significantly reduce the variability and inaccuracy in the component alignment parameters that lead to post-operative complications, including implant failure.


Eligibility criteria:
inclusion criteria: * male or female * 20 to 75 years of age * subjects requiring primary total hip replacement * contralateral hip should be relatively free from arthritis for comparison purposes, specifically with less than a grade of 2 on the kellgren-lawrence scale. * subjects diagnosed with osteoarthritis or traumatic arthritis * subjects with avascular necrosis * subjects who demonstrate the ability to return for follow-up for the next 10 years exclusion criteria: * subjects with difficulty understanding protocol for any reason * subjects with a limited life span * subjects with inflammatory hip disease, previous joint infection, or those requiring hip revision surgery * female subjects who are pregnant, or who plan to get pregnant while enrolled in the study

Keywords: robotic arthroplasty total hip arthroplasty cup positioning outcomes
daily step count using pedometer for sarcopenic management in patient with cirrhosis: randomized controlled trial

Conditions: Sarcopenia; Cirrhosis, Liver; Daily Step Count

Summary: the goal of clinical trial is to compare using pedometer in sarcopenic cirrhotic patients. the main questions it aims to answer are: 1. did the encourage using pedometer group had higher change of skeletal muscle index (smi) than discourage using pedometer group? 2. how many of patients who had sarcopenic improvement in both groups at 6 months after enrollment? 3. what is the mortality rate and hospital admission in both groups at 12 months after enrollment?


Eligibility criteria:
inclusion criteria: * 1. age 18 - 75 years old * 2. cirrhotic patient with diagnosed sarcopenia * 3. patients or caregiver who can write and announce thai language * 4. cirrhotic patient who was post liver transplantation \> 1 year exclusion criteria: * 1. cirrhosis child-turcotte-pugh (ctp) c \> 10 2. refractory ascites 3. decompensated comorbidity: heart failure nyha iii-iv, esrd with dialysis, copd gold d 4. performance status ecog 3-4 5. bone fracture within 4 weeks or limitation of activity 6. pregnancy and breastfeeding 7. hcc during treatment with tace or microwave ablation or radiofrequency ablation within 6 months before enrollment 8. advanced stage malignancy 9. received chemotherapy 10. muscle weakness disease 11. recent cerebrovascular disease within 6 months and motor weakness grade \ 2 times/year

Keywords: sarcopenia liver cirrhosis daily step count pedometer recording
canine assisted therapy to reduce emergency care provider stress

Conditions: Stress; Anxiety

Summary: the main study hypothesis is that emergency healthcare workers on shift who interact for 5 min with a therapy dog and handler will have lower perceived and manifested stress response compared with use of a time out that includes voluntary use of a coloring mandalas. the work will also address two exploratory hypotheses: the first is that salivary cortisol will correlate significantly with perceived stress and will increase from beginning to end of shift, and that exposure to a therapy dog will blunt this increase. the second exploratory hypothesis states that participants who interact with a therapy dog will display more empathic behaviors.


Eligibility criteria:
inclusion criteria: * inclusion criteria require that participants work full time as either a nurse or physician in the eskenazi emergency department and are willing to consent to participation. * participants will include residents, faculty and nurses who work in the emergency department exclusion criteria: * exclusions include any reported prior fear or adverse reaction to dogs

Keywords: stress anxiety cortisol therapy dog coloring mandala
genotype information and functional testing study

Conditions: Coronary Artery Disease

Summary: this study is a sub-study of gravitas (clinicaltrials.gov identifier nct00645918). the purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.

as described by the pi: this study is a sub-study of gravitas (clinicaltrials.gov identifier nct00645918). the purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.

Eligibility criteria:
inclusion criteria: * patients meeting inclusion criteria for gravitas who undergo verifynow blood sampling for verifynow p2y12 platelet function testing and ivrs entry for gravitas randomization/selection determination exclusion criteria: * see gravitas trial (clinicaltrials.gov identifier: nct00645918)

Keywords: thienopyridine platelets cyp2c19 clopidogrel platelet function tests platelet genes cytochrome p450 single nucleotide polymorphisms platelet aggregation inhibitors
swimming and water walking on spirometry values

Conditions: Child Development; Child Obesity; BMI

Summary: to study the effects of swimming with water walking in children aged between 6 and 12 years in terms of spirometric values.

the present research aims to verify if there are differences in body composition and spirometric values in children aged between 6 and 12 years who practice swimming complemented with water walking at the end of each session and those who only practice swimming. the sample consisted of 28 individuals aged 6 to 12 years and was divided into two groups: swimming group (sg) with 9 children and swimming complemented with water walking group (swwg) of 19 children. in this study, the investigators wanted to know which were the benefits in body composition and for that purpose used a bio-impedance scale targa silvercrest z29777a (germany), and an anthropometric tape to measure the waist circumference. to calculate the spirometric values, namely forced vital capacity (fvc), forced expiratory volume in 1 second (fev1) and even peak expiratory flow (pef) a cosmed microquark spirometer was used. in terms of statistical procedures, the investigators used the program statistical package for the social sciences version number 20 (spss 20.0). the investigators used descriptive statistics (minimum, maximum, means and standard deviations), the shapiro wilk test for testing the normality of the sample, inferential statistics (non-parametric mann-whitney tests, friedman's anova, and for the calculation of the effect magnitude the d-cohen test). after the data treatment, regarding the inter-group analysis (comparison between the swimming group and the swimming group with water walking) the investigators observed that there were significant differences in three variables at the end of the study, that is, at the end of the 3 moments. these variables were weight relative to body composition, forced expiratory volume in 1 second (fev1) and peak expiratory flow (pef), these values are relative to the spirometry evaluation. concerning intra-group differences (improvement in the swimming group and the swimming with water walking group in the three moments evaluated), the swwg showed significant improvements in the variables of weight, muscle mass, fat mass, percentage of water, body mass index (bmi), body percentiles, forced vital capacity (fvc) and forced expiratory volume in 1 second (fev1).

Eligibility criteria:
inclusion criteria: * children inside this age range; * water experience between 6 and 12 months * children with no other activities besides swimming exclusion criteria: * children with asma; * children with dpoc * children with pulmonary limitations.
a trial of lidocaine patch for lower limb amputation pain

Conditions: Phantom Limb Pain (PLP); Primary/Secondary Scar Hyperalgesia

Summary: phantom limb pain (plp) and scar hyperalgesia (sh) are frequent problems after amputation; in particular most persons who undergo limb amputation will experience phantom pain. the neuropathic nature of plp suggests the involvement of both peripheral and central neurological mechanisms, including neuroplastic changes in the central nervous system. plp as other central nervous system-related pain syndromes remains a challenge for treatment. scar hyperalgesia involves peripheral mechanisms and results frim the production of substances liberated by damaged skin cells. these inflammatory substances lower the pain threshold by altering the chemical environment of skin nerve endings. scan hyperalgesia is associated with secondary mechanical hyperalgesia in the skin area around the scar. the lidocaine patch 5% is a topical analgesic acting by blocking sodium channels of peripheral nerve endings and by inhibiting ectopic discharges in sensitized and hyperactive cutaneous nociceptors. the patch is noninvasive, with minimal systemic absorption resulting in a reduced risk of drug-drug interaction. in addition, a central analgesic effect of lidocaine has been suggested. the lidocaine patch 5% is currently licensed for the treatment of symptomatic postherpetic neuralgia. it also has been successfully used in patients with other neuropathic pain states, such as entrapment neuropathies, painful idiopathic distal sensory polyneuropathies and postoperative/post traumatic neuropathic chronic cutaneous pain. the lidocaine patch has not been studied for the management and prevention of phantom limb pain. the aim of the present research is to investigate if a lidocaine patch 5% is effective for reducing plp and primary/secondary scar hyperalgesia. the hypothesis is that persistent peripheral nociceptive input from the stump after surgery may drive maladaptive cortical reorganization leading to chronic central pain and thus promote chronic phantom limb pain. treating scar hyperalgesia on the stump with topical lidocaine may reduce the activity of peripheral nociceptive afferents and thus decrease the likelihood of developing persistent phantom limb pain. this study is designed as a randomized controlled multicentric double blind trial, in which the effectiveness of applying a 5% lidocaine patch for 6 weeks will be compared with a sham.


Eligibility criteria:
inclusion criteria: * all above or below knee amputations , two months or more after surgery, after complete wound healing (no clips, no stitches, no seepage) exclusion criteria: * history of central nervous system disease * history of major psychiatric disease (mms\ 8/21) * pregnancy * known hypersensitivity to local anesthetics (lidocaine, bupivacaine, etidocaine, mepivacaine, prilocaine) * skin irritation on the stump

Keywords: lidocaine phantom limb pain (plp) primary/secondary scar hyperalgesia
assessment of efficacy and safety of ruxolitinib in participants with covid-19-associated ards who require mechanical ventilation (ruxcovid-devent)

Conditions: COVID-19

Summary: the purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with covid-19-associated acute respiratory distress syndrome (ards) who require mechanical ventilation.


Eligibility criteria:
inclusion criteria: * participant or guardian health proxy must provide informed consent before any study assessment is performed. * male or female participants aged ≥ 12 years. * participants with coronavirus (sars-cov-2) infection confirmed ≤ 3 weeks prior to randomization by any test with local regulatory approval. * participants who are intubated and receiving mechanical ventilation due to covid-19-associated ards and have a pao2/fio2 of ≤ 300 mmhg within 6 -hours of randomization. participants with lung imaging showing bilateral or diffuse pulmonary infiltrates on chest x-ray or ct scan. exclusion criteria: * known history of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib. * presence of severely impaired renal function defined by estimated creatinine clearance \< 15 ml/min measured or calculated by cockcroft-gault equation or calculated by the updated bedside schwartz equation. participants must not be receiving crrt or intermittent hemodialysis at screening. * in the opinion of the investigator, unlikely to survive for \> 24 hours from randomization. * suspected active uncontrolled bacterial, fungal, viral, or other infection (besides covid-19). * currently receiving ecmo. * participant may not be sharing a ventilator, or co-ventilating, with any other patient. * treatment with anti-il-6, il-6r, il-1ra, il-1β, or gm-csf antagonists, or a btk inhibitor, within 7 days of randomization. * treatment with a jak inhibitor within 30 days of randomization. * participants who are on long-term use of antirejection or immunomodulatory drugs. * pregnant or nursing (lactating) women.

Keywords: cytokine storm covid-19 ards sars-cov-2 ruxolitinib pneumonia
prevention of venous thromboembolism in patients undergoing elective total hip replacement surgery

Conditions: Venous Thromboembolism

Summary: the purpose of this study is to examine the superiority of ym150 to the placebo and to evaluate the dose-dependent response of ym150 in patients undergoing elective total hip replacement surgery.


Eligibility criteria:
inclusion criteria: * subjects is scheduled for elective primary total hip replacement surgery * written informed consent obtained before screening exclusion criteria: * subject has history of deep vein thrombosis and/or pulmonary embolism * subject has a hemorrhagic disorder and/or coagulation disorder * subject has had clinically important bleeding occurred within 90 days prior to the screening visit * subject has an acute bacterial endocarditis, retinopathy, hypertension, or thrombocytopenia * subject is receiving anticoagulants/antiplatelet agents

Keywords: ym150 fxa inhibitor thrombosis anticoagulant venous thromboembolism arthroplasty, replacement, hip
evaluation of catheter placement for renal replacement therapy in patients with acute kidney injury

Conditions: Acute Kidney Injury

Summary: the purpose of this study is to examine the placement, timing, associated complications, efficacy of temporary and tunneled catheters for renal replacement therapy in patient with acute kidney injury.

the purpose of this study is to examine the placement, timing, associated complications, efficacy of temporary and tunneled catheters for renal replacement therapy in patient with acute kidney injury. in particular, we will be assessing renal replacement adequacy for patients on dialysis and continuous veno-venous hemofiltration by monitoring urea reduction ratios, venous and arterial pressures. we will also be monitoring infection rates. we will compare these outcomes in patients receiving tunneled catheters and patients receiving temporary catheters.

Eligibility criteria:
inclusion criteria: * patients admitted to the hospital with acute kidney injury requiring renal replacement therapy exclusion criteria: * end stage renal disease * chronic kidney disease 5 progression to end stage renal disease * outside hospital catheter placement
omega-3 and cardiovascular risk factors and kidney related biomarkers

Conditions: Cardiovascular Risk Factor and Kidney Related Biomarkers

Summary: in this study, 99 overweight or obese women that referred to the clinic nutrition to lose weight were randomly divided into three groups according to body mass index (bmi) by random-number table (figure1). we attempted to match all three groups for bmi, probable medications, and age. subjects were excluded if they had risk factors of cardiovascular diseases or allergic reactions to fish or walnut, or received lowering blood glucose or lipid profile agents. also, participants with weak economic status could not enter to this study (due to the high cost of fish and walnuts). before the start of this study, the information in the form of questionnaire about demographic, medical history, and medication use, was completed. participants were aware about overview of this study, and completed the consent form. the national instituted for medical research development (nimad), approved all procedures involving human subjects. the study has been done in accordance with the ethical standards in declaration of helsinki. then all of the three groups received a low-calorie diet in order to lose weight. the distribution of macronutrients was similar in three groups (carbohydrate 55%, fat 33%, and protein 17%). the amount of different fatty acids (saturated, unsaturated with mono double bond, and polyunsaturated fatty acids) intake in these diets was the same but the sources of omega-3 between these groups were different. in the first group, subjects were instructed to consume 300 gram fatty fish, such as salmon fish during a week in two separated meals (each meal 150 gr fatty fish) and to avoid consumption of plant sources of omega-3 (soybean oil, canola, flaxseed and walnuts). in the second group, subjects were asked to consume walnuts three times a week and each time two walnuts (totally 18 walnuts/wk) and avoid the consumption of fish. and in the third group, subjects were recommended to consume 150 g fatty fish during a week and nine walnuts. the amount of omega-3 fatty acids considered in this study covered the typical recommended intake (0.3 to 0.5 g/d of epa+dha and 0.8 to 1.1 g/d of ala)(14). dietary intakes of all patients were controlled by a dietitian and they were followed for 12 weeks. dietary intakes were assessed by three dietary records (one weekend and two week days).

this is a clinical trial which conducted on over weight and obese female.

Eligibility criteria:
inclusion criteria: * over weight or obese exclusion criteria: * have any diseases